-
-
SAN FRANCISCO "It's not buying a car it's the driving that makes the difference."
-
ALEXANDRIA, Virginia Cartoonist and author Scott Adams of "Dilbert" fame is credited with having said that some of the "nutty methods" for predicting the future include reading tarot cards and tea leaves. Or, "you can put well-researched facts into sophisticated computer models more commonly referred to as 'a complete waste of time."
-
Don't put all your eggs in one basket or so the saying goes.
-
Abbott Vascular (Santa Clara, California) earlier this month submitted an application for Shonin marketing authorization license to Japan's Ministry of Health, Labor and Welfare/Pharmaceuticals and Medical Devices Agency to gain approval for its Xience V everolimus-eluting coronary stent system to treat coronary artery disease.
-
AngioDynamics; Diomed Holdings; Diomed; Applera; Celera Group; Berkeley HeartLab; Boston Scientific; CryoCor; MedCath; Good Samaritan Hospital; Dayton Heart Hospital; Mindray Medical International; Datascope; Royal Philips Electronics; Dixtal Biomédica e Tecnologia; Spectranetics; Kensey Nash; Volcano; Novelis
-
Averion International; Boston Scientific; Cambridge Heart; CoreValve; Invatec-USA; LifeWatch; MedCath; South Dayton Surgeons; Ohio State Medical Association; Kettering Medical Center
-
Siemens Healthcare (Mountain View, California) unveiled its Acuson SC2000 volume imaging ultrasound system, which it says is the first system to acquire non-stitched, real-time full-volume 3-D images of the heart in one single heart cycle, during the 19th annual meeting of the American Society of Echocardiography (ASE; Raleigh, North Carolina) in Toronto.
-
Diabetes and cardiovascular disease are closely linked, with a high percentage of those with diabetes dying of a cardiovascular illness or event. This is well-recognized, but the relationship between the two diseases is obviously complex.
-
A study published in a recent issue of the Journal of the American Society of Hypertension demonstrates that the hypertension treatment olmesartan medoxomil was effective in reversing the narrowing of the arteries that occurs in patients with hypertension. The study, Vascular Improvement with Olmesartan medoxomil Study (VIOS), was a one-year, exploratory trial that evaluated the effects of an angiotensin receptor blocker (olmesartan medoxomil) vs. a beta-blocker (atenolol) on vascular function and structure in patients with Stage 1 hypertension, independent of the blood pressure lowering effects of these agents.
